Evidence based on recent studies Initially, cases of intestinal obstruction associated with GLP-1 RAs were reported by the European Medicines Agency (EMA) in 2013 [9], and this safety signal is currently being monitored by the United States (US) FDA
PEPerchini Scientific does not provide dosing, administration, injection, reconstitution-for-injection or treatment guidance
GLP-1 medications are part of our medical weight loss program
However, it is essential to approach their use thoughtfully, integrating them into a comprehensive lifestyle plan and working closely with a knowledgeable clinician
What Are the Side Effects and Risks of Retatrutide
For some, a lower maintenance dose can keep weight steady